Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab.
Alexander KrezeMatěj HomerTereza BarešováKristina KlemperováPublished in: Endocrine oncology (Bristol, England) (2022)
Treatment with immune checkpoint inhibitors (ICIs) is associated with many endocrine side effects.It is recommended that patients treated with ICIs are observed by an endocrinologist.If side effects are treated accordingly, ICI therapy can continue.
Keyphrases